Developer of a drug designed to treat nocturia. The company's patented drug assist in treating the frequent need to urinate at night and to eliminate nocturia symptoms which can be disseminated, enabling patients to sleep well at night without using the bathroom.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Later Stage VC (Series D) | 18-Apr-2016 | $10M | 000.00 | 0000 | Completed | Clinical Trials - Phase 2 |
3. Later Stage VC (Series C) | 01-Apr-2015 | 00.00 | 00.000 | 0000 | Completed | Clinical Trials - Phase 2 |
2. Angel (individual) | 01-Oct-2014 | $550K | $1.05M | 000.00 | Completed | Clinical Trials - Phase 2 |
1. Angel (individual) | 11-Jun-2014 | $500K | $500K | 000.00 | Completed | Clinical Trials - Phase 2 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
David Dill | Founder, Chief Executive Officer, President & Chairman |
Name | Representing | Role | Since |
---|---|---|---|
David Dill | Wellesley Pharmaceuticals | Founder, Chief Executive Officer, President & Chairman | 000 0000 |
John Balian | Wellesley Pharmaceuticals | Board Member | 000 0000 |
Michael Myers Ph.D | Self | Board Member | 000 0000 |
Growth Rate
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialInvestor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Axella Bioventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Keiretsu Forum | Venture Capital | Minority | 000 0000 | 000000 0 |